144 related articles for article (PubMed ID: 38589463)
21. Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis.
Lei JH; Liu LR; Wei Q; Song TR; Yang L; Meng Y; Han P
Asian J Androl; 2016; 18(1):102-7. PubMed ID: 25851657
[TBL] [Abstract][Full Text] [Related]
22. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225
[TBL] [Abstract][Full Text] [Related]
23. Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate.
Li X; Xi H; Cheng X; Yu Y; Zhang C; Wang G; Zhou X
Front Endocrinol (Lausanne); 2023; 14():1123934. PubMed ID: 36843605
[TBL] [Abstract][Full Text] [Related]
24. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
25. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513
[TBL] [Abstract][Full Text] [Related]
26. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Morgans AK; Chen YH; Sweeney CJ; Jarrard DF; Plimack ER; Gartrell BA; Carducci MA; Hussain M; Garcia JA; Cella D; DiPaola RS; Patrick-Miller LJ
J Clin Oncol; 2018 Apr; 36(11):1088-1095. PubMed ID: 29522362
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
28. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
Spratt DE; Malone S; Roy S; Grimes S; Eapen L; Morgan SC; Malone J; Craig J; Dess RT; Jackson WC; Hartman HE; Kishan AU; Mehra R; Kaffenberger S; Morgan TM; Reichert ZR; Alumkal JJ; Michalski J; Lee WR; Pisansky TM; Feng FY; Shipley W; Sandler HM; Schipper MJ; Roach M; Sun Y; Lawton CAF
J Clin Oncol; 2021 Jan; 39(2):136-144. PubMed ID: 33275486
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James ND; de Bono JS; Spears MR; Clarke NW; Mason MD; Dearnaley DP; Ritchie AWS; Amos CL; Gilson C; Jones RJ; Matheson D; Millman R; Attard G; Chowdhury S; Cross WR; Gillessen S; Parker CC; Russell JM; Berthold DR; Brawley C; Adab F; Aung S; Birtle AJ; Bowen J; Brock S; Chakraborti P; Ferguson C; Gale J; Gray E; Hingorani M; Hoskin PJ; Lester JF; Malik ZI; McKinna F; McPhail N; Money-Kyrle J; O'Sullivan J; Parikh O; Protheroe A; Robinson A; Srihari NN; Thomas C; Wagstaff J; Wylie J; Zarkar A; Parmar MKB; Sydes MR;
N Engl J Med; 2017 Jul; 377(4):338-351. PubMed ID: 28578639
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
31. Effect of Exercise Adjunct to Radiation and Androgen Deprivation Therapy on Patient-Reported Treatment Toxicity in Men With Prostate Cancer: A Secondary Analysis of 2 Randomized Controlled Trials.
Schumacher O; Galvão DA; Taaffe DR; Spry N; Joseph D; Tang C; Chee R; Newton RU
Pract Radiat Oncol; 2021; 11(3):215-225. PubMed ID: 33540038
[TBL] [Abstract][Full Text] [Related]
32. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy.
Faria S; Ruo R; Cury F; Duclos M; Souhami L
Pract Radiat Oncol; 2017; 7(4):264-269. PubMed ID: 28222995
[TBL] [Abstract][Full Text] [Related]
33. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
Krauss DJ; Karrison T; Martinez AA; Morton G; Yan D; Bruner DW; Movsas B; Elshaikh M; Citrin D; Hershatter B; Michalski JM; Efstathiou JA; Currey A; Kavadi VS; Cury FL; Lock M; Raben A; Seaward SA; El-Gayed A; Rodgers JP; Sandler HM
J Clin Oncol; 2023 Jun; 41(17):3203-3216. PubMed ID: 37104748
[TBL] [Abstract][Full Text] [Related]
34. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
Hershman DL; Unger JM; Wright JD; Ramsey S; Till C; Tangen CM; Barlow WE; Blanke C; Thompson IM; Hussain M
JAMA Oncol; 2016 Apr; 2(4):453-61. PubMed ID: 26720308
[TBL] [Abstract][Full Text] [Related]
35. Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
Movsas B; Rodgers JP; Elshaikh MA; Martinez AA; Morton GC; Krauss DJ; Yan D; Citrin DE; Hershatter BW; Michalski JM; Ellis RJ; Kavadi VS; Gore EM; Gustafson GS; Schulz CA; Velker VM; Olson AC; Cury FL; Papagikos MA; Karrison TG; Sandler HM; Bruner DW
J Clin Oncol; 2023 Jun; 41(17):3217-3224. PubMed ID: 37104723
[TBL] [Abstract][Full Text] [Related]
36. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.
Norkus D; Karklelyte A; Engels B; Versmessen H; Griskevicius R; De Ridder M; Storme G; Aleknavicius E; Janulionis E; Valuckas KP
Radiat Oncol; 2013 Sep; 8():206. PubMed ID: 24007322
[TBL] [Abstract][Full Text] [Related]
37. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
39. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
Bryant AK; Kader AK; McKay RR; Einck JP; Mell LK; Mundt AJ; Kane CJ; Efstathiou JA; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1188-1193. PubMed ID: 29891203
[TBL] [Abstract][Full Text] [Related]
40. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
